The stock of Krystal Biotech Inc (KRYS) has seen a -5.39% decrease in the past week, with a -0.15% drop in the past month, and a -30.18% decrease in the past quarter. The volatility ratio for the week is 2.08%, and the volatility levels for the past 30 days are at 2.09% for KRYS. The simple moving average for the past 20 days is 0.73% for KRYS’s stock, with a -21.13% simple moving average for the past 200 days.
Is It Worth Investing in Krystal Biotech Inc (NASDAQ: KRYS) Right Now?
The price-to-earnings ratio for Krystal Biotech Inc (NASDAQ: KRYS) is 31.81x, which is above its average ratio. Moreover, the 36-month beta value for KRYS is 0.66. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for KRYS is 24.81M and currently, short sellers hold a 11.77% of that float. On June 19, 2025, KRYS’s average trading volume was 346.97K shares.
KRYS) stock’s latest price update
Krystal Biotech Inc (NASDAQ: KRYS)’s stock price has soared by 1.59 in relation to previous closing price of 130.02. Nevertheless, the company has seen a loss of -5.39% in its stock price over the last five trading days. zacks.com reported 2025-06-05 that Krystal Biotech (KRYS) reported earnings 30 days ago. What’s next for the stock?
Analysts’ Opinion of KRYS
Many brokerage firms have already submitted their reports for KRYS stocks, with Jefferies repeating the rating for KRYS by listing it as a “Buy.” The predicted price for KRYS in the upcoming period, according to Jefferies is $245 based on the research report published on March 05, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see KRYS reach a price target of $204, previously predicting the price at $195. The rating they have provided for KRYS stocks is “Neutral” according to the report published on August 06th, 2024.
Goldman gave a rating of “Buy” to KRYS, setting the target price at $160 in the report published on November 20th of the previous year.
KRYS Trading at -9.03% from the 50-Day Moving Average
After a stumble in the market that brought KRYS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.78% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KRYS starting from Krishnan Suma, who sale 25,000 shares at the price of $177.79 back on Mar 13 ’25. After this action, Krishnan Suma now owns 1,533,056 shares of Krystal Biotech Inc, valued at $4,444,763 using the latest closing price.
Krishnan Suma, the President, R&D of Krystal Biotech Inc, sale 25,000 shares at $177.79 during a trade that took place back on Mar 13 ’25, which means that Krishnan Suma is holding 1,463,711 shares at $4,444,761 based on the most recent closing price.
Stock Fundamentals for KRYS
Current profitability levels for the company are sitting at:
- 0.36 for the present operating margin
- 0.93 for the gross margin
The net margin for Krystal Biotech Inc stands at 0.37. The total capital return value is set at 0.12. Equity return is now at value 13.90, with 12.86 for asset returns.
Based on Krystal Biotech Inc (KRYS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 14.33.
Currently, EBITDA for the company is 109.91 million with net debt to EBITDA at -2.3. When we switch over and look at the enterprise to sales, we see a ratio of 10.55. The receivables turnover for the company is 3.23for trailing twelve months and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.65.
Conclusion
To wrap up, the performance of Krystal Biotech Inc (KRYS) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
